A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCR5 + CD8 + T cells present elevated capacity in mediating cytotoxicity toward autologous tumor cells through interleukin 10 in diffuse large B-cell lymphoma

(2017) Jiahong Tang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

(2017) Deborah Charych et al.   PLoS One

CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

(2016) Zhenhua Ren et al.   CLINICAL CANCER RESEARCH

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals

(2016) Marie T. Kim et al.   JOURNAL OF IMMUNOLOGY

Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection

(2016) Ran He et al.   NATURE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Timing of Stimulation and IL-2 Signaling Regulate Secondary CD8 T Cell Responses

(2015) Shaniya H. Khan et al.   PLoS Pathogens

Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses

(2014) Xuanming Yang et al.   CANCER CELL

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

(2014) Denise Skrombolas et al.   Expert Review of Clinical Immunology

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice

(2014) K. L. Gutbrodt et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival

(2013) Richard K. Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

(2013) Geok Choo Sim et al.   JOURNAL OF CLINICAL INVESTIGATION

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells

(2012) YU-JIA DU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity

(2011) S. D. Gillies et al.   CLINICAL CANCER RESEARCH

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacologic Administration of Interleukin-2

(2009) Antonio Romo de Vivar Chavez et al.   Annals of the New York Academy of Sciences

Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma

(2009) H. K. Jensen et al.   CLINICAL CANCER RESEARCH